- Raised $2M funding round, Jan 2019
About
Galimedix is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta plays a role, such as in dry AMD, glaucoma and Alzheimer’s disease: Galimedix’s initial areas of focus.
Its amyloid beta-targeting approach is strongly supported by our license deal with a major ophthalmology player, as well as recent successes in the field of Alzheimer’s disease.
Galimedix’s approach blocks a key step in the neurodegenerative process with a highly specific, well tolerated small molecule without impacting normal neuronal function. This key step – the formation of toxic oligomers and protofibrils of amyloid beta (Aβ) – has emerged as a central cause of neurodegeneration. This understanding is supported by recent approvals and by positive late-stage clinical results with Aβ-targeting therapies for Alzheimer’s disease, as well as numerous publications about the role of Aβ in dry AMD and glaucoma.
Funding history · 1 round · $2.0M total
Q&A
- What is Galimedix Therapeutics' primary focus?
- Galimedix Therapeutics is a Phase 2 clinical-stage company developing novel oral and topical neuroprotective therapies for serious eye and brain diseases, specifically targeting conditions where amyloid beta plays a role, such as dry AMD, glaucoma, and Alzheimer’s disease.
- When was Galimedix Therapeutics founded?
- Galimedix Therapeutics was founded in June 2017.
- How much funding has Galimedix Therapeutics raised to date?
- Galimedix Therapeutics has raised a total of $2,000,000.
- Which investors participated in Galimedix Therapeutics' funding round in January 2019?
- In January 2019, Galimedix Therapeutics received funding from InFocus Capital Partners and Rimonci Capital.
- What is the current employee count for Galimedix Therapeutics?
- Galimedix Therapeutics has 1-10 employees.
- Where is Galimedix Therapeutics headquartered?
- Galimedix Therapeutics is headquartered in Shorashim, Israel.
- Does Galimedix Therapeutics hold any patents?
- Yes, Galimedix Therapeutics holds 1 patent.
- Who are the co-founders of Galimedix Therapeutics?
- The co-founders of Galimedix Therapeutics are Christopher Parsons, Herman Russ, and Andrew Pearlman.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | galimedix.com |
|---|---|
| linkedin.com/company/42904523 |
Identifiers & details
| Founded | 2017-6 |
|---|---|
| Employees (exact) | 10 |
| Offices | Kensington |
Radar intelligence
Patents
| EPO | 7 |
|---|
Web history (Wayback)
| Domain | galimedix.com |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|